The brand new data display effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered right to the substantia nigra in the CNS of non-human primates. Alpha-synuclein is broadly believed to play a central role in the advancement of Parkinson’s disease, where the accumulation of surplus alpha-synuclein protein in the substantia nigra offers been linked to the cause and/or progression of the disease. Indeed, immediate delivery of RNAi therapeutics in the CNS represents a significant element of our overall item development strategy,’ stated David Bumcrot, Ph.D., Director, Analysis at Alnylam.In addition, managing the complete patient might help reduce hospitalizations, readmissions and emergency department visits, helping manage overall costs. The CVS Caremark Insights record addresses prescription drug use for members with prescription benefits provided by CVS Caremark during the 2013 calendar year. The 2013 cohort studied includes 22.9 million members across the commercial segments along with Medicare Part D and Medicaid programs. Access the entire CVS Caremark Insights report at: information.cvscaremark.com/insights-trend2014.. ‘Brain-computer interface’ advancement receives Arizona Biomedical Analysis Commission grant Efforts to progress technology to aid those who have lost conversation and movement skills are receiving support from an Arizona Biomedical Study Commission grant for a task combining resources and knowledge at Arizona Condition University and the Children’s Neuroscience Institute in Phoenix Children’s Medical center.